- Design
- Two replicate randomised, placebo-controlled phase 3 trials (OBERON, TITANIA), 52 weeks
- Population
- About 870 adults per trial with COPD and prior exacerbations on inhaled maintenance therapy
- Primary outcome
- Annualised rate of moderate or severe exacerbations in former smokers
- Effect
- Rate ratio 0.71 (95% CI 0.57 to 0.88) in OBERON; 0.66 (95% CI 0.55 to 0.80) in TITANIA
OBERON and TITANIA were replicate phase 3 trials of add-on subcutaneous tozorakimab 300 mg every 4 weeks versus placebo for 52 weeks in adults with COPD, a history of exacerbations despite stable inhaled maintenance therapy, and no blood eosinophil requirement. Tozorakimab inhibits interleukin-33.
The primary endpoint was the annualised rate of moderate or severe exacerbations in former smokers. In OBERON the rate was 1.34 vs 1.90 (rate ratio 0.71, 95% CI 0.57 to 0.88), and in TITANIA 1.37 vs 2.07 (0.66, 0.55 to 0.80). In the overall population, rates were 1.41 vs 2.00 (0.70, 0.58 to 0.85) and 1.44 vs 2.03 (0.71, 0.59 to 0.84). Each trial enrolled about 870 patients. Adverse events were 70.4% vs 77.2% in OBERON and 80.1% vs 79.8% in TITANIA.
The abstract reports exacerbation rates only; effects on lung function, hospital admission and mortality are not given, and the sponsor funded the trials. The regulatory status and availability in India are not established here. Inhaler technique, vaccination, smoking cessation and pulmonary rehabilitation remain the first steps.
- Check inhaler technique, adherence, vaccination and smoking status before considering any add-on for frequent exacerbations.
- Record exacerbations in the past year; this trial population all had them despite maintenance therapy.
- Do not expect to prescribe this yet; regulatory status and access in India are not established.
- Watch for further reporting on hospitalisations, lung function and long-term safety.
Why it matters
It suggests a new target, IL-33, may help patients with COPD whatever their eosinophil count.
Don't overread it
Only exacerbation rate is reported in the abstract, and the sponsor funded the trials; this is not an approval or a guideline change.
The statistics, in plain English
A rate ratio of 0.70 means about 30% fewer moderate or severe exacerbations per year than placebo; in absolute terms about 0.6 fewer exacerbations per patient-year. Two replicate trials pointing the same way make a chance finding less likely than one trial alone.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for top clinical updates, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free